Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis Antimicrobial Agents & Chemotherapy, (2019) 63 (10) e01078-19
In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015–2017 Diagnostic Microbiology and Infectious Disease, Volume 95, Issue 4, December 2019, 114879
Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus Antimicrobial Agents & Chemotherapy, (2019) 63 (6) e02616-18
The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis Antimicrobial Agents & Chemotherapy, (2019) 63 (4) e02291-18
Bacteriophage Lysin CF-301: a Potent Anti-Staphylococcal Biofilm Agent Antimicrob. Agents Chemother (2017) 61 (7) e02666-16
Combination Therapy with Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus-Induced Murine Bacteremia Journal of Infectious Diseases, (2014) 209 (9): 1469-1478.
Lysins Exhibit Potent Bactericidal Activity, Synergy and Antibiofilm Effects against Pseudomonas aeruginosa in Human Serum and Pulmonary Surfactant Presented at ASM 2019, June 23, 2019
Bacteriophage Lysin CF-301 (Exebacase) in Addition to Daptomycin in a Simulated Endocardial Vegetation (SEV) PK/PD Model Presented at ASM 2019, June 23, 2019
PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models Presented at ASM 2019, June 21, 2019
Pharmacodynamic Assessment of Lysin CF-301 (exebacase) in Addition to Daptomycin against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model Presented at ASM 2019, June 21, 2019
Lysin GN123 Resensitizes Cabapenem-Resistant Pseudomonas aeruginosa to Imipenem Presented at ECCMID 2019, April 13, 2019
Lysin exebacase (CF-301) exhibits potent bactericidal activity in human synovial fluid against biofilm-forming Staph epidermidis isolates Presented at ECCMID 2019, April 13, 2019
Comparison of Lysin CF-301 (exebacase) Activity Against S. aureus Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates Presented at ID Week 2018, October 5, 2018
CF-301 (Exebacase) Resensitizes Methicillin-Resistant Staphylococcus aureus (MRSA) to Penicillin Derivatives and First Generation Cephalosporins Presented at ASM-ESCMID 2018, September 4, 2018
Bacteriophage Lysins Can Be Engineered to Exert a Rapid and Potent Bactericidal Effect against Pseudomonas aeruginosa in Serum Presented at ASM 2018, June 10, 2018
Lysin CF-301 Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis Presented at ASM 2018, June 10, 2018
